Medicinal chemistry – Page 62
-
FeatureGiving screening the green light
Chemists are working with toxicologists at an earlier stage to avoid problems further down the chain, as Emma Davies reports
-
FeatureRe-arming the antibiotic arsenal
How can we make new antibiotics? Phillip Broadwith takes a look
-
CareersNon-profit pharma
Not-for-profit drug discovery is growing into a promising niche employment opportunity within the pharmaceutical industry. James Mitchell Crow investigates
-
BusinessService with a smile
Company profile: Charnwood Molecular is more than a run-of-the-mill contract synthesis provider
-
Business
GSK criticised for trial data secrecy
Italian research institute abandons collaboration over data access
-
NewsCall to overhaul liver toxicity testing
Outdated tests could be causing drug candidates to be scrapped without reason, say scientists
-
-
News
AllTrials releases plan for clinical trial reporting
Public campaign sets out how trial data should be made public
-
NewsAnimal testing failures put drug trial volunteers in danger
Poor pre-clinical data and an absence of negative results are pushing candidate molecules into the clinic too soon
-
FeatureAnimal pharm
Making drugs to treat animals is potentially lucrative – but also difficult, as Clare Sansom discovers
-
News
Former student sues Harvard for $10 million
PhD chemist seeks damages in row over patent royalties
-
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
Companies urged to publish hidden clinical trial data
Researchers could acquire data and publish themselves if firms refuse
-
News'Scientific censorship' hamstringing psychoactive drug research
New treatments for psychological disorders are being held back by government controls on recreational drugs
-
OpinionCompulsory licences: necessity or threat?
Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?
-
-
-
BusinessClinical trial data release blocked by companies
Abbvie and Intermune sue the European Medicines Agency to stop it making data public